Soleno Therapeutics announced on Tuesday the voluntary withdrawal of its European marketing application for Vykat XR, a drug aimed at treating hyperphagia associated with Prader-Willi syndrome. This decision comes as part of a strategic shift following the company's acquisition by Neurocrine Biosciences for $2.9 billion. Neurocrine's CEO, Kyle Gano, indicated that the company will focus on launching the drug in the U.S. market and currently has no plans for a European launch. The European Medicines Agency was expected to make a decision on the drug by mid-2026. This withdrawal aligns with a growing trend among pharmaceutical companies to delay new medicine launches in Europe amid changing U.S. pricing policies. Following the announcement, shares of Neurocrine fell by 1.1%.